Carmell Corp. Faces Delisting Notice
Ticker: XAGEW · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1842939
| Field | Detail |
|---|---|
| Company | Carmell Corp (XAGEW) |
| Form Type | 8-K |
| Filed Date | Oct 3, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50, $1 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, corporate-actions
TL;DR
Carmell Corp. got a delisting warning, stock might be in trouble.
AI Summary
Carmell Corp. filed an 8-K on October 3, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of September 30, 2024. The company, formerly known as ALPHA HEALTHCARE ACQUISITION CORP III and Carmell Therapeutics Corp, is incorporated in Delaware and headquartered in Pittsburgh, PA.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the liquidity and valuation of Carmell Corp.'s stock.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading status and investor confidence.
Key Numbers
- 001-40228 — Commission File Number (Identifies the company's SEC filings)
- 86-1645738 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Carmell Corp. (company) — Registrant
- ALPHA HEALTHCARE ACQUISITION CORP III (company) — Former Company Name
- Carmell Therapeutics Corp (company) — Former Company Name
- September 30, 2024 (date) — Date of earliest event reported
- October 3, 2024 (date) — Date of Report
- 2403 Sidney Street, Suite 300, Pittsburgh, PA 15203 (address) — Business and Mail Address
FAQ
What specific listing rule or standard did Carmell Corp. fail to satisfy?
The filing does not specify the exact rule or standard that Carmell Corp. failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard was issued.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated September 30, 2024.
What were Carmell Corp.'s previous names?
Carmell Corp. was formerly known as Carmell Therapeutics Corp and ALPHA HEALTHCARE ACQUISITION CORP III.
Where is Carmell Corp. headquartered?
Carmell Corp. is headquartered at 2403 Sidney Street, Suite 300, Pittsburgh, PA 15203.
What is the filing date of this 8-K report?
This 8-K report was filed on October 3, 2024.
Filing Stats: 809 words · 3 min read · ~3 pages · Grade level 15.7 · Accepted 2024-10-03 16:30:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CTCX The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 CTCXW The Nasdaq Stock Market LLC
- $1 — ment to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listi
Filing Documents
- ctcx-20240930.htm (8-K) — 39KB
- 0000950170-24-112392.txt ( ) — 181KB
- ctcx-20240930.xsd (EX-101.SCH) — 44KB
- ctcx-20240930_htm.xml (XML) — 6KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 30, 2024, Carmell Corporation, a Delaware corporation (the "Company"), received a letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that, based upon the closing bid price of the Company's common stock for the 31 consecutive business days from August 15, 2024 to September 27, 2024, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has provided the Company with 180 calendar days, or until March 31, 2025 (the "Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company's common stock must be at least $1 per share for a minimum of ten consecutive business days at any time during this 180-day period, after which Nasdaq will provide written confirmation of compliance to the Company and the matter will be closed. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, Nasdaq may grant the Company an additional compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement if the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement, and provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period. However, if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency or if the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 3, 2024 By: /s/ Bryan J. Cassaday Bryan J. Cassaday Chief Financial Officer